Immunological Identification of Vaginal Secretions, Urine, and Other Fluids

Vaginal secretions are a forensically significant fluid in sexual-assault casework, yet they lack a simple presumptive test equivalent to the peroxidase-based test for blood. Cytological identification using ferning patterns or Trichomonas vaginalis microscopy has been used historically, but these methods have poor sensitivity on dried or aged stains. Immunological approaches targeting fluid-specific proteins offer greater reliability.

Human leucocyte elastase (HLE) has emerged as the most extensively validated immunological marker for vaginal secretions. HLE is a serine protease expressed by vaginal epithelial cells and cervical mucus-secreting cells. It is not present at detectable levels in semen, blood, or saliva under normal conditions, though menstrual discharge can contain low levels due to the leucocyte infiltration that accompanies menses. ELISA-based detection of HLE was first proposed for forensic use in the 1990s; lateral-flow formats adapted from clinical diagnostic products became the focus of validation studies in the 2010s.

The SERATEC HE Test is the most widely cited commercial lateral-flow product for this purpose. Peer-reviewed studies have shown sensitivity on vaginal swab extracts aged up to several weeks when stored dry at room temperature, though sensitivity declines on stains exposed to humidity, direct sunlight, or bleach. Cross-reactivity with semen has been reported in some studies at high concentration, because semen contains elastase from neutrophil infiltration in males with asymptomatic genital tract infection. This is a source of potential false positives in mixed-fluid samples.

Matrix metalloproteinase-2 (MMP-2) has been evaluated as an additional marker. MMP-2 is secreted by vaginal fibroblasts and is present in cervicovaginal fluid. Used in combination with HLE, it can increase specificity. However, MMP-2 is not fluid-exclusive in the same way that HLE is, and its use as a confirmatory marker remains more common in research settings than in operational case work.

Urine identification in forensic casework arises most commonly in cases of secondary transfer (a suspect's clothing may bear urine contact-stain from a victim), in scenes where the location of urination is disputed, and in sexual assault where urine may be mixed with other biological fluids. Classical urine detection relies on creatinine measurement or ultraviolet fluorescence, both of which lack specificity. Immunological confirmation using a urine-specific protein marker offers higher evidential value.

Tamm-Horsfall protein (THP), now formally named uromodulin, is produced exclusively in the kidney's thick ascending loop of Henle and is the most abundant protein in normal human urine. It is absent from blood, saliva, semen, and vaginal secretions under healthy conditions. ELISA formats for THP detection have been applied forensically with reported limits of detection in the nanogram-per-millilitre range. Lateral-flow formats designed for clinical urothelial infection monitoring have been adapted for forensic stain screening.

Published forensic validation data for THP-based assays show reliable detection on stains aged one to four weeks under dry indoor conditions. Environmental exposure to high humidity or temperature accelerates protein degradation. One important caveat is that proteinuria (elevated urinary protein in renal disease) or unusual dietary states can alter THP concentration, potentially lowering sensitivity. In cases where the sample donor has known renal disease, this limitation should be considered.

Distinguishing menstrual blood from peripheral blood is forensically significant in several contexts: determining the timing of a blood deposit in relation to a menstrual cycle, assessing claims that a bloodstain arose from natural menstrual loss rather than injury, and investigating sexual-assault scenes where menstrual blood may be present alongside semen. Classical haematological tests confirm the presence of blood but cannot discriminate between its two sources.

Menstrual blood differs from peripheral blood in its cellular composition and protein profile. The endometrial shedding process involves high levels of matrix metalloproteinases, particularly MMP-10, produced by endometrial stromal cells during menstruation. MMP-10 is present in menstrual blood at concentrations orders of magnitude higher than in peripheral blood, making it a suitable discriminatory marker. A lateral-flow assay targeting MMP-10 was developed and published by several research groups from 2009 onward. Commercial products, including the RSID-Menstrual Blood kit (Independent Forensics, Illinois), use this principle and have been subjected to forensic validation studies.

Fibronectin has also been proposed as a secondary marker for menstrual blood. Fibronectin is a glycoprotein present in endometrial fluid during menstrual shedding at elevated levels compared to peripheral blood. Combined MMP-10 and fibronectin detection increases the reliability of menstrual blood identification, though MMP-10 alone is considered sufficient by most published protocols. Validation studies from multiple forensic laboratories have confirmed the discrimination of menstrual blood from peripheral blood, saliva, semen, and vaginal secretions with high specificity when MMP-10 LFIA is used under standard conditions.

Sweat is deposited on items handled or worn by a person and can be a source of DNA from shed epithelial cells. Confirming that a substrate contains sweat, rather than another fluid, is less frequently required in case work but is relevant when the mode of contact is disputed. The challenge is that sweat contains only trace levels of proteins, most of which are also present in other secretions.

Dermcidin is a 110-amino-acid antimicrobial peptide secreted constitutively by eccrine sweat glands and cleaved into smaller peptide fragments with antimicrobial activity. It is expressed specifically in eccrine glands and is present in sweat at detectable concentrations but is largely absent from serum, saliva, semen, and vaginal secretions at equivalent dilutions. As such, it has been proposed as an immunological marker for sweat identification. Antibody-based assays capable of detecting dermcidin in sweat stain extracts have been described in research publications, but no commercially validated forensic kit was available as of the early 2020s.

The forensic maturity of sweat identification lags behind the other three fluid types reviewed in this topic. The primary reason is that sweat identification rarely changes case outcomes on its own: the evidential weight of sweat confirmation is usually lower than that of semen or blood confirmation. Research has therefore been less intensive. RNA-based sweat identification using tissue-specific messenger RNA markers has been proposed as a parallel approach and may offer higher specificity than protein-based methods.

Every immunological body-fluid assay in forensic use must be validated before casework application. Validation requirements include: demonstration of specificity against a panel of other body fluids and common interferents, sensitivity across a range of stain ages and substrates, reproducibility across operators and instruments, and stability data for the kit reagents. The scope of validation expected varies by jurisdiction: the UK Forensic Regulator's guidance requires peer-reviewed or laboratory-internal validation following ISO 17025 principles; the US FBI and OSAC guidance sets analogous requirements; and the European Network of Forensic Science Institutes (ENFSI) provides quality guidelines applicable across member laboratories.

Cross-reactivity is the main analytical limitation. Antibodies raised against a target protein will occasionally bind to structurally similar proteins in other fluids. For HLE in vaginal secretion testing, cross-reactivity with semen elastase is the most documented concern. For THP in urine testing, no significant cross-reactivity with other body fluids has been reported, making it among the most specific of the fluid markers. For MMP-10 in menstrual blood testing, some studies report weak reactivity with tissue extracts that contain endometrial-type cells, but this is rarely encountered in forensic casework.

Stain age and environmental conditions degrade the protein markers that immunoassays target. The general order of stability in dried stains under room temperature conditions, from most to least stable, is: haemoglobin markers for blood, THP for urine, HLE for vaginal secretions, MMP-10 for menstrual blood. Sweat marker dermcidin degrades rapidly. In practice, a negative immunological result on an aged or environmentally compromised sample cannot be interpreted as confirming the absence of the fluid, only as a failure to detect the marker.

Body-fluid immunoassay results contribute to case reconstruction and should be interpreted alongside other evidence streams. In sexual-assault casework, a positive HLE result on a vaginal swab from a complainant, combined with a positive PSA result confirming semen, and a DNA profile matching a suspect, builds a coherent evidential picture. The HLE result adds evidence that the sexual contact involved vaginal penetration, not merely external contact with secretions.

Menstrual blood identification is most significant when a suspect claims a blood deposit arose from a complainant's menstrual loss rather than from a wound. A positive MMP-10 result is consistent with that claim; a negative MMP-10 result on a large blood deposit makes it less likely. Neither result is conclusive without other supporting context, but MMP-10 discrimination changes the weight of the evidence in a measurable way.

Urine identification arises less often as a central issue but can be significant in scenes involving domestic violence (blood and urine may both be present), in cases where a suspect denies having been at a scene in which urination is documented, or in cases where drug-facilitated assault is alleged and a urine stain from a victim may be recoverable from bedding or clothing. Confirming THP in a stain allows the DNA or toxicological analysis to proceed with a defined fluid-type context.

The integration of immunological body-fluid identification with RNA-based methods is an active research direction. Messenger RNA profiling using tissue-specific transcripts (for example, CYP2B7P1 and MYOZ1 for vaginal secretions, MMP11 for menstrual blood) can confirm fluid type from the same biological sample used for DNA extraction. When both protein immunoassay and RNA profiling are available, they provide orthogonal evidence of fluid type, increasing confidence in the identification. The RNA approach is more sensitive on aged stains where proteins have degraded but nucleic acids remain detectable.